Professor Wu Yilong led the way: How to break the situation after EGFR mutation lung cancer targeted therapy resistance?

*For medical professionals to read for reference only Comprehensive assessment, analysis and discussion of the disease condition to jointly formulate a scientific, reasonable and standardized treatment plan can effectively improve the survival rate and quality of life of cancer patients
.

Since 2003, the Guangdong Provincial Lung Cancer Research Institute of Guangdong Provincial People's Hospital, under the leadership of Professor Wu Yilong, has carried out multidisciplinary case discussions on lung cancer every Wednesday afternoon.
Over the past two decades, it has provided thousands of patients with better diagnosis and treatment decisions.
It has also cultivated the ability of multidisciplinary thinking and collaboration among many oncologists
.

On this basis, in March 2021, the Lung Oncology Branch of the Guangdong Medical Association and the Guangdong Clinical Trials Association/China Thoracic Oncology Research Assistance Group (GACT/CTONG) will organize various specialties in the clinical field of lung cancer in Guangdong Province.
The experts from the hospital carried out a monthly "Guangdong General Consultation" project for difficult cases of lung cancer.
During the 10 consultations, experts in various fields showed their strengths, arguing, brainstorming, and applying the evidence of evidence-based medicine to specific personalities.
In the case of chemical treatment, it fully embodies that "medicine is an art based on science"
.

Through online live broadcast and major media reports, the project has a wide influence in the domestic lung cancer clinical medical community, and has played a good role in promoting the standardized multidisciplinary diagnosis and treatment of lung cancer
.

Encouraged by the successful holding of the "Guangdong Conference", in order to gather the wisdom of experts from a wider range and promote the multidisciplinary expert diagnosis and treatment model for lung cancer, the Lung Oncology Branch of the Guangdong Medical Association and the Guangdong Clinical Trials Association/China The Thoracic Oncology Research Assistance Group (GACT/CTONG) has jointly launched the "China Thoracic Oncology Conference" event in February 2022, which is currently the first nationwide expert on-site consultation event for lung cancer and other thoracic tumors
.

We will invite experts from all over the country in the field of thoracic tumor treatment to form a consultation decision-making team, and regularly conduct multidisciplinary consultations on representative and difficult cases of lung cancer every month.
Contribute to the tough task of diagnosis and treatment of lung cancer in China
.

* The medical community strives for the accuracy and reliability of its published content when it is approved, but does not make any commitments and guarantees about the timeliness of the published content, and the accuracy and completeness of the cited materials (if any), and does not assume any any liability arising out of the date of such content, possible inaccuracies or incompleteness of the material cited
.

Relevant parties are requested to check separately when adopting or using it as a basis for decision-making
.

The 2022 CSCO Academic Annual Meeting, co-organized by the Beijing Heathco Clinical Oncology Research Foundation and the Chinese Society of Clinical Oncology (CSCO), is exclusively co-organized by the medical community - the Heathco Foundation's second "One Hundred' Cases" Large-scale Case Collection The event is here! 25 "direct" 2022 CSCO annual meeting places to scan the code to sign up, you may be the one who will be on the stage!